USANA Health Sciences, Inc. - 2005 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: USANA Health Sciences, Inc.
Reporting Period: Fiscal year ended December 31, 2005 (52-week year).
Business Model: USANA develops, manufactures, and distributes science-based nutritional and personal care products primarily through a network marketing system using independent "Associates." A secondary channel involves direct sales to "Preferred Customers" for personal use.
Segments: Operations are divided into Direct Selling (97.5% of net sales) and Contract Manufacturing (2.5% of net sales).
Geography: Operations span North America (64.8% of sales) and the Pacific Rim (32.7% of sales), including markets in the U.S., Canada, Mexico, Australia, New Zealand, Hong Kong, Japan, Taiwan, South Korea, and Singapore.
Key Financial Metrics (Fiscal Year 2005)
| Metric | 2005 Value | 2004 Value | Change |
|---|---|---|---|
| Net Sales | $327.7 million | $272.8 million | +20.1% |
| Gross Profit | $249.7 million | $206.0 million | +21.2% |
| Gross Margin | 76.2% | 75.5% | +0.7 pts |
| Net Earnings | $39.0 million | $30.8 million | +26.7% |
| Diluted EPS | $1.98 | $1.51 | +31.1% |
| Operating Cash Flow | $48.0 million | $38.2 million | +25.7% |
| Cash & Equivalents (End of Period) | $10.6 million | $15.1 million | -29.8% |
| Long-Term Debt | $0 | $0 | N/A |
| Working Capital | $15.3 million | $18.1 million | -15.5% |
Note: Associate incentives totaled $128.7 million, representing 40.3% of Direct Selling segment net sales.
Material Changes vs. Prior Period
- Revenue Growth: Driven by a 16.7% increase in active Associates (to 133,000) and an 11.1% increase in Preferred Customers (to 70,000). Stronger foreign currencies contributed an additional $7.8 million to reported sales.
- Segment Performance: Direct Selling sales grew $57.1 million. Contract Manufacturing sales declined $2.2 million due to a strategic shift away from third-party business to focus on internal Sensé production.
- Margin Expansion: Gross margin improved to 76.2% due to leverage on rising sales and a reduced impact from the lower-margin Contract Manufacturing segment.
- Liquidity Impact: Cash and working capital decreased significantly due to $49.2 million utilized for share repurchases under the company's stock buyback program.
- Acquisitions: Acquired a manufacturing facility in Tianjin, China, for $1.4 million in October 2005 to support future expansion.
Guidance, Outlook, and Risks
Management Guidance (2006):
- Sales Growth: Anticipated net sales growth between 15% and 20%.
- Earnings Per Share: Expected to grow 15% to 20%, excluding the impact of new stock-based compensation accounting rules (SFAS No. 123(R)).
- Accounting Impact: Implementation of SFAS No. 123(R) in 2006 is expected to decrease EPS by approximately $0.14.
- Expense Outlook: Associate incentives are expected to rise to approximately 41% of Direct Selling net sales due to new promotional initiatives. SG&A expenses are expected to increase as a percentage of sales due to step-function costs and new equity compensation expensing.
- Regulatory Environment: New Chinese regulations (effective Dec 2005) prohibit multi-level compensation models, potentially delaying or altering market entry strategies. Ongoing scrutiny by the FTC regarding advertising claims and network marketing practices.
- Supply Chain: Historical shortages of raw materials (e.g., CoQ10) have impacted margins, though supply has stabilized as of mid-2005.
- Associate Turnover: Revenue is dependent on the recruitment and retention of independent Associates, who have high turnover rates.
- Foreign Exchange: Significant exposure to currency fluctuations; a strengthening U.S. dollar could negatively impact reported earnings.
- Capital Expenditures: Approximately $9 million committed for corporate headquarters expansion in 2006.
Investor Verification Checklist
- Associate Growth Quality: Verify the sustainability of the 16.7% increase in active Associates and the productivity per Associate to ensure revenue growth is not solely volume-driven.
- Share Repurchase Impact: Assess the impact of the $49.2 million share buyback on liquidity and the company's ability to fund the planned $9 million facility expansion without external financing.
- China Market Entry: Monitor progress on regulatory approvals for the Chinese market given the new restrictions on multi-level marketing compensation models.
- Stock-Based Compensation: Review the pro-forma impact of SFAS No. 123(R) adoption in 2006 on future earnings per share.
- Contract Manufacturing Strategy: Confirm the strategic rationale for the decline in third-party contract manufacturing sales and the profitability of the new China facility.